Clinical and Laboratory Results in Five Patients After As2O3 Treatment
| Before As2O3Treatment . | Days of Receiving As2O3 Treatment . | After As2O3 Treatment . | |||||
|---|---|---|---|---|---|---|---|
| Case No. . | BM . | BM . | |||||
| Promyelocyte (%) . | Myelocyte (%) . | Metamyelocyte (%) . | Promyelocyte (%) . | Myelocyte (%) . | Metamyelocyte (%) . | ||
| 21 | 93 | 1.5 | 1 | 28 | 0.5 | 15.5 | 18.5 |
| 22 | 73 | 1 | 0 | 12 | 5.5 | 44.5 | 27 |
| 29 | 75 | 8.5 | 2 | 18 | 79 | 5 | 0 |
| 35 | 11 | 22.5 | 0 | 25 | 0.5 | 54.5 | 0 |
| 37 | 64.5 | 10 | 3 | 22 | 6 | 45 | 13 |
| Before As2O3Treatment . | Days of Receiving As2O3 Treatment . | After As2O3 Treatment . | |||||
|---|---|---|---|---|---|---|---|
| Case No. . | BM . | BM . | |||||
| Promyelocyte (%) . | Myelocyte (%) . | Metamyelocyte (%) . | Promyelocyte (%) . | Myelocyte (%) . | Metamyelocyte (%) . | ||
| 21 | 93 | 1.5 | 1 | 28 | 0.5 | 15.5 | 18.5 |
| 22 | 73 | 1 | 0 | 12 | 5.5 | 44.5 | 27 |
| 29 | 75 | 8.5 | 2 | 18 | 79 | 5 | 0 |
| 35 | 11 | 22.5 | 0 | 25 | 0.5 | 54.5 | 0 |
| 37 | 64.5 | 10 | 3 | 22 | 6 | 45 | 13 |